Drugs / RAVOXERTINIB
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02457793 | Jun 2015 → Dec 2016 | colorectal cancer, metastatic melanoma, non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01875705 | Jun 2013 → Sep 2016 | cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RAVOXERTINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544964 ↗ |
| Known as | GDC-0994 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01875705 ↗ |
| Known as | RG-7842 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3544964 ↗ |
| Action | Inhibit | “MAP kinase ERK2 inhibitor” CHEMBL3544964 ↗1“MAP kinase ERK1 inhibitor” CHEMBL3544964 ↗ |
| Modality | Small molecule | — CHEMBL3544964 ↗ |
| Route | Oral | “oral dosing of cobimetinib and GDC-0994 administered in combination” NCT02457793 ↗ |
| Target | MAPK1 | “MAP kinase ERK2 inhibitor” CHEMBL3544964 ↗ |
| Target | MAPK3 | “MAP kinase ERK1 inhibitor” CHEMBL3544964 ↗ |